ODTX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Odyssey Therapeutics, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 18.93 USD
1.4% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is - below the Trend Line and sits at 73.7% of its 52-week range. The latest completed week returned 1.4%, after a 12.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 45d.

Setup score 39 out of 100
Latest Close 18.93 USD 31 Jul 2026
1W Return 1.4% latest completed week
4W Return 12.7% short-term follow-through
12W Return 15.3% quarterly tape
Trend Breadth 0.0% 0 of 13 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Activity pressure is negative, which weakens the current setup.
  • Next-week expectancy is negative at 43.97% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.4% Latest completed week; four-week move 12.7%. Indicator stack 0/50 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.97% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 40 relevant articles in the latest sentiment read. Event risk 45d Next report is scheduled for 16 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is - below the Trend Line and sits at 73.7% of its 52-week range. The latest completed week returned 1.4%, after a 12.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.02

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 12.7% over four weeks, 15.3% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.4%
4W12.7%
12W15.3%
26W-
52W-
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength47/100Blend of value, momentum, and quality. Underlying universe rank 54; rank 1 is best.
Value48/100Relative valuation strength. Underlying universe rank 53; rank 1 is best.
Quality47/100Profitability and accounting quality. Underlying universe rank 54; rank 1 is best.
Momentum48/100Medium-term price momentum. Underlying universe rank 53; rank 1 is best.
Growth48/100Revenue and earnings growth. Underlying universe rank 53; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
301.2x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-14.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
100.0%
Gross profit retained from each unit of revenue.
Operating margin
-5025.4%
Operating profit retained from revenue.
Free-cash-flow margin
-4309.0%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-33.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-23.7%
Net share repurchases relative to market value.
Shareholder yield
-23.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 40 relevant articles.

5 positive · 32 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings45dNext report is scheduled for 16 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-6.7%Distance below the 52-week high.
13-week volatility5.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher6 of 126 weeks finished lower.
Best week+12.8%Week of 19 Jun.
Worst week-7.0%Week of 3 Jul.
Latest week+1.4%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains2
Flat weeks0
Modest losses4
Sharp losses2
Recent vol5.6%13-week weekly-return volatility.
Base vol5.6%52-week weekly-return volatility.
Up/down split6/6Count of positive and negative weeks in the 52-week window.
Average skew6.0% / -3.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape30/100

Trend, activity pressure, participation, and risk combine to a 30/100 tape read.

 Indicator analysis6/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.07; 2 reversal markers Next-Week ExpectancyNegative 43.97%

Next-week expectancy is negative with a 43.97% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors46/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 92; Small Cap Core rank 55 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 40 relevant articles.

ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.020|Chg%:-0.410 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings45d

Next report is scheduled for 16 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202618.93 USD1.4%-17.52 USD0.00-794.1KOff
24 Jul 202618.66 USD6.0%-17.40 USD0.00-854.9KOff
17 Jul 202617.61 USD5.5%-17.28 USD0.00-2.2MOff
10 Jul 202616.69 USD-0.7%-17.25 USD0.00-1.5MOff
3 Jul 202616.80 USD-7.0%-17.31 USD0.00-1.4MOff
26 Jun 202618.06 USD-5.3%-17.38 USD0.00-1.5MOff
19 Jun 202619.07 USD12.8%-17.28 USD0.00-2.8MOff
12 Jun 202616.90 USD2.9%-16.98 USD0.00-1.4MOff
5 Jun 202616.43 USD-3.4%-17.00 USD0.00-1.5MOff
29 May 202617.01 USD-2.8%-17.14 USD0.00-1.3MOff
22 May 202617.50 USD-0.7%-17.18 USD--1.9MOff
15 May 202617.62 USD7.3%-17.02 USD--1.7MOff
8 May 202616.42 USD--16.42 USD--3.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.